Episode Details
Back to Episodes
BIO-Europe 2025: Anavo Therapeutics is focused on phosphatases - and is publicly talking about its two lead programs for the first time
Published 10 months, 1 week ago
Description
CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.